Alteogen Partnership: Biogen's recent licensing agreement with Alteogen for Hybrozyme-based subcutaneous biologics has sparked optimism on social media. Investors highlight the $20 million upfront payment and potential milestones exceeding $500 million as a boost to the company's pipeline. The deal underscores Biogen's push into advanced drug delivery technologies.
Technical Breakout: Shares of Biogen surged past the 50-day moving average in pre-market trading amid the news. Social media traders note potential upside toward $190 at key trendlines. This momentum reflects growing confidence in the stock's near-term trajectory.
Pipeline Progress: Discussions also touch on Biogen's phase 1 data for an LRRK2-targeting therapy in Parkinson's, showing significant biomarker reductions. Enthusiasm builds around ongoing advancements in neurology and rare diseases. Overall sentiment leans bullish on strategic developments.
Note: This discussion summary was generated from an AI condensation of post data.
Biogen Insider Trading Activity
Biogen insiders have traded $BIIB stock on the open market 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:
- PRIYA SINGHAL (Head of Development) has made 0 purchases and 2 sales selling 3,408 shares for an estimated $665,664.
- NICOLE MURPHY (Head of Pharm Ops and Tech) purchased 3 shares for an estimated $585
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Biogen Revenue
Biogen had revenues of $2.3B in Q4 2025. This is a decrease of -7.14% from the same period in the prior year.
You can track BIIB financials on Quiver Quantitative's BIIB stock page.
Biogen Congressional Stock Trading
Members of Congress have traded $BIIB stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 01/30.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Biogen Hedge Fund Activity
We have seen 456 institutional investors add shares of Biogen stock to their portfolio, and 453 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 8,138,103 shares (+632.0%) to their portfolio in Q4 2025, for an estimated $1,432,224,746
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 4,365,462 shares (-75.8%) from their portfolio in Q4 2025, for an estimated $768,277,657
- BOSTON PARTNERS added 1,720,595 shares (+inf%) to their portfolio in Q4 2025, for an estimated $302,807,514
- PACER ADVISORS, INC. removed 1,451,249 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $255,405,311
- POINT72 ASSET MANAGEMENT, L.P. removed 1,059,709 shares (-27.4%) from their portfolio in Q4 2025, for an estimated $186,498,186
- FRED ALGER MANAGEMENT, LLC added 796,735 shares (+39074.8%) to their portfolio in Q4 2025, for an estimated $140,217,392
- INVESCO LTD. removed 762,686 shares (-31.5%) from their portfolio in Q4 2025, for an estimated $134,225,109
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Biogen Analyst Ratings
Wall Street analysts have issued reports on $BIIB in the last several months. We have seen 3 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 01/30/2026
- HSBC issued a "Reduce" rating on 12/10/2025
- Stifel issued a "Buy" rating on 11/06/2025
- RBC Capital issued a "Outperform" rating on 10/31/2025
To track analyst ratings and price targets for Biogen, check out Quiver Quantitative's $BIIB forecast page.
Biogen Price Targets
Multiple analysts have issued price targets for $BIIB recently. We have seen 19 analysts offer price targets for $BIIB in the last 6 months, with a median target of $200.0.
Here are some recent targets:
- Rajesh Kumar from HSBC set a target price of $150.0 on 03/17/2026
- Emily Field from Barclays set a target price of $185.0 on 02/20/2026
- Laura Chico from Wedbush set a target price of $187.0 on 02/10/2026
- Mohit Bansal from Wells Fargo set a target price of $200.0 on 02/09/2026
- David Amsellem from Piper Sandler set a target price of $177.0 on 02/09/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $228.0 on 02/09/2026
- Geoff Meacham from Citigroup set a target price of $215.0 on 02/09/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
